SBRT + Atezolizumab + Bevacizumab in Resectable HCC
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Active, not recruiting · NCT04857684 · Registry updated 2025-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SBRT + Atezolizumab + Bevacizumab in Resectable HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Early phase 1 | 2025-10-01 | NCT04857684 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Massachusetts General Hospital | 758 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |